FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017386225> ?p ?o ?g. }

• W2017386225 endingPage "949" @default.
• W2017386225 startingPage "939" @default.
• W2017386225 abstract "Objective: Hepatitis B surface (HBsAg) and envelope (HBeAg) antigen loss are the primary goals of treating chronic hepatitis B virus (HBV). Although their quantification is useful for other antivirals, such has not been the case with tenofovir disoproxil fumarate (TDF), particularly in HIV infection. Design: Prospective, multicenter, cohort study in 143 antiretroviral-experienced HIV–HBV-co-infected patients initiating TDF. Methods: HBsAg (IU/ml) and HBeAg levels (S/CO) were measured every 6 months. HBsAg and HBeAg decline (Δ) were assessed by mixed-effect linear models. Quantification criteria were used to assess predictability of antigen loss with time-dependent receiver operating characteristic curves. Results: After a median follow-up of 30.3 months, cumulative incidence rate of HBsAg loss was 4.0% (n = 4) in the entire study population and HBeAg loss was 21.0% (n = 17) in the 96 HBeAg-positive patients. ΔHBsAg was steady during follow-up (HBeAg-positive: −0.027; HBeAg-negative: −0.017 log10 IU/ml per month), whereas ΔHBeAg ratio was strongly biphasic (−27.1 S/CO per month before and −6.5 S/CO per month after 18 months). Baseline HBeAg and ΔHBeAg were significantly different in patients harboring precore mutations (P < 0.01), whereas both ΔHBsAg and ΔHBeAg were significantly slower among HBeAg-positive patients with CD4+ T-cell count less than 350 cells/μl (P < 0.05). HBeAg-ratio of 10 S/CO or less at 12 months of therapy was the optimal marker of HBeAg loss, with high sensitivity (0.82) and specificity (0.84) at 36 months. In patients with HBsAg loss, three of four (75.0%) patients had a baseline level of HBsAg of 400 IU/ml or less. Conclusion: During TDF treatment, HIV-induced immunosuppression and HBV genetic variability are associated with differences in HBsAg and HBeAg decline among antiretroviral-experienced, co-infected patients. Considering the decline of HBsAg level is slow, further evaluation is needed to determine its role as a marker of therapeutic efficacy." @default.
• W2017386225 created "2016-06-24" @default.
• W2017386225 creator A5000901517 @default.
• W2017386225 creator A5013566909 @default.
• W2017386225 creator A5018051281 @default.
• W2017386225 creator A5022180654 @default.
• W2017386225 creator A5026085361 @default.
• W2017386225 creator A5026642894 @default.
• W2017386225 creator A5030341745 @default.
• W2017386225 creator A5030725109 @default.
• W2017386225 creator A5033891876 @default.
• W2017386225 creator A5063172143 @default.
• W2017386225 creator A5070585467 @default.
• W2017386225 date "2012-05-15" @default.
• W2017386225 modified "2023-10-18" @default.
• W2017386225 title "Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV–hepatitis B virus-infected patients" @default.
• W2017386225 cites W118409507 @default.
• W2017386225 cites W175109609 @default.
• W2017386225 cites W1841441057 @default.
• W2017386225 cites W1966772739 @default.
• W2017386225 cites W1971078289 @default.
• W2017386225 cites W1972782591 @default.
• W2017386225 cites W1986634163 @default.
• W2017386225 cites W1991855620 @default.
• W2017386225 cites W1997681955 @default.
• W2017386225 cites W2006011870 @default.
• W2017386225 cites W2006701618 @default.
• W2017386225 cites W2009509017 @default.
• W2017386225 cites W2018196002 @default.
• W2017386225 cites W2023718741 @default.
• W2017386225 cites W2030522797 @default.
• W2017386225 cites W2033837061 @default.
• W2017386225 cites W2046196885 @default.
• W2017386225 cites W2074676714 @default.
• W2017386225 cites W2082534929 @default.
• W2017386225 cites W2094798000 @default.
• W2017386225 cites W2095029196 @default.
• W2017386225 cites W2099591808 @default.
• W2017386225 cites W2107074922 @default.
• W2017386225 cites W2123473148 @default.
• W2017386225 cites W2123664981 @default.
• W2017386225 cites W2133717458 @default.
• W2017386225 cites W2135201594 @default.
• W2017386225 cites W2156015715 @default.
• W2017386225 cites W2157039129 @default.
• W2017386225 cites W2330570786 @default.
• W2017386225 cites W2332247812 @default.
• W2017386225 cites W2397954892 @default.
• W2017386225 cites W3030265267 @default.
• W2017386225 doi "https://doi.org/10.1097/qad.0b013e328352224d" @default.
• W2017386225 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22333748" @default.
• W2017386225 hasPublicationYear "2012" @default.
• W2017386225 type Work @default.
• W2017386225 sameAs 2017386225 @default.
• W2017386225 citedByCount "44" @default.
• W2017386225 countsByYear W20173862252012 @default.
• W2017386225 countsByYear W20173862252013 @default.
• W2017386225 countsByYear W20173862252014 @default.
• W2017386225 countsByYear W20173862252015 @default.
• W2017386225 countsByYear W20173862252016 @default.
• W2017386225 countsByYear W20173862252017 @default.
• W2017386225 countsByYear W20173862252018 @default.
• W2017386225 countsByYear W20173862252019 @default.
• W2017386225 countsByYear W20173862252020 @default.
• W2017386225 countsByYear W20173862252021 @default.
• W2017386225 countsByYear W20173862252023 @default.
• W2017386225 crossrefType "journal-article" @default.
• W2017386225 hasAuthorship W2017386225A5000901517 @default.
• W2017386225 hasAuthorship W2017386225A5013566909 @default.
• W2017386225 hasAuthorship W2017386225A5018051281 @default.
• W2017386225 hasAuthorship W2017386225A5022180654 @default.
• W2017386225 hasAuthorship W2017386225A5026085361 @default.
• W2017386225 hasAuthorship W2017386225A5026642894 @default.
• W2017386225 hasAuthorship W2017386225A5030341745 @default.
• W2017386225 hasAuthorship W2017386225A5030725109 @default.
• W2017386225 hasAuthorship W2017386225A5033891876 @default.
• W2017386225 hasAuthorship W2017386225A5063172143 @default.
• W2017386225 hasAuthorship W2017386225A5070585467 @default.
• W2017386225 hasBestOaLocation W20173862251 @default.
• W2017386225 hasConcept C126322002 @default.
• W2017386225 hasConcept C159047783 @default.
• W2017386225 hasConcept C203014093 @default.
• W2017386225 hasConcept C2522874641 @default.
• W2017386225 hasConcept C2775940106 @default.
• W2017386225 hasConcept C2777382497 @default.
• W2017386225 hasConcept C2777410769 @default.
• W2017386225 hasConcept C2780593183 @default.
• W2017386225 hasConcept C71924100 @default.
• W2017386225 hasConcept C90924648 @default.
• W2017386225 hasConceptScore W2017386225C126322002 @default.
• W2017386225 hasConceptScore W2017386225C159047783 @default.
• W2017386225 hasConceptScore W2017386225C203014093 @default.
• W2017386225 hasConceptScore W2017386225C2522874641 @default.
• W2017386225 hasConceptScore W2017386225C2775940106 @default.
• W2017386225 hasConceptScore W2017386225C2777382497 @default.
• W2017386225 hasConceptScore W2017386225C2777410769 @default.
• W2017386225 hasConceptScore W2017386225C2780593183 @default.
• W2017386225 hasConceptScore W2017386225C71924100 @default.

• next